Phlexglobal is a leading provider of technology-enabled document management solutions to the life sciences industry.
The company is a specialist provider of Trial Master File (TMF) and electronic Trial Master File (eTMF) solutions, combining clinical trial knowledge, document management skills, regulatory understanding and technical expertise.
Bridgepoint Development Capital (“BDC”) engaged DC Advisory (“DC”) to provide M&A and debt advice on the acquisition of Phlexglobal, drawing on the DC team's detailed knowledge of the pharma services sector.
A highly competitive and fully documented debt financing package was secured by DC's Debt Advisory Group on a tight buyside timetable.
On 11 July 2014, BDC announced the acquisition of Phlexglobal for £42 million.
We are delighted to have had the chance to work with BDC on their acquisition of Phlexglobal the company is a market-leader offering valued specialist services, and we are confident that it will thrive under BDC’s ownership.